CLC number:
On-line Access: 2024-08-27
Received: 2023-10-17
Revision Accepted: 2024-05-08
Crosschecked: 0000-00-00
Cited: 0
Clicked: 771
Hongying YE, Weijie LIAO, Jiongli PAN, Yin SHI, Qingqing WANG. Immune checkpoint blockade for cancer therapy: current progress and perspectives[J]. Journal of Zhejiang University Science B, 1998, -1(-1): .
@article{title="Immune checkpoint blockade for cancer therapy: current progress and perspectives",
author="Hongying YE, Weijie LIAO, Jiongli PAN, Yin SHI, Qingqing WANG",
journal="Journal of Zhejiang University Science B",
volume="-1",
number="-1",
pages="",
year="1998",
publisher="Zhejiang University Press & Springer",
doi="10.1631/jzus.B2300492"
}
%0 Journal Article
%T Immune checkpoint blockade for cancer therapy: current progress and perspectives
%A Hongying YE
%A Weijie LIAO
%A Jiongli PAN
%A Yin SHI
%A Qingqing WANG
%J Journal of Zhejiang University SCIENCE B
%V -1
%N -1
%P
%@ 1673-1581
%D 1998
%I Zhejiang University Press & Springer
%DOI 10.1631/jzus.B2300492
TY - JOUR
T1 - Immune checkpoint blockade for cancer therapy: current progress and perspectives
A1 - Hongying YE
A1 - Weijie LIAO
A1 - Jiongli PAN
A1 - Yin SHI
A1 - Qingqing WANG
J0 - Journal of Zhejiang University Science B
VL - -1
IS - -1
SP -
EP -
%@ 1673-1581
Y1 - 1998
PB - Zhejiang University Press & Springer
ER -
DOI - 10.1631/jzus.B2300492
Abstract: The dysfunction of anti-tumor immune responses is crucial for cancer progression. immune checkpoint blockade (ICB), which could potentiate T cell responses, is an effective strategy for the normalization of host anti-tumor immunity. In recent years, immune checkpoints, expressed on both tumor cells and immune cells, have been identified; some of them have exhibited potential druggability and have been approved by the Food and Drug Administration (FDA) for clinical treatments. However, the limited responses and immune-related adverse events (irAEs) cannot be ignored. This review outlines the development and applications of ICBs, potential strategies for overcoming resistance, and future directions for ICB-based cancer immunotherapy.
Open peer comments: Debate/Discuss/Question/Opinion
<1>